Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Moderna has secured FDA approval for its respiratory syncytial virus (RSV ... and Pfizer’s products. There’s still one more step before Moderna’s vaccine can take on Arexvy and Abrysvo ...

That shot, Abrysvo, brought in $198 million in the quarter, missing expectations by more than $300 million. Pfizer’s RSV vaccine has struggled to compete with one from GSK in a market that now ...

On the flip side, vaccines Prevnar and Abrysvo underperformed expectations. Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered ...

GSK (GSK) and Pfizer (PFE) vaccines for respiratory syncytial virus, or RSV, will carry warnings that ... of GSK’s Arexvy and Pfizer’s Abrysvo are not the regulator’s strictest “boxed ...

An example is Pfizer Inc., which received FDA approval for its RSV Vaccine, ABRYSVO, in October 2024. It expanded its indication to the broadest adult population and remains the only approved RSV ...

However, sales of some key drugs like Prevnar, Xeljanz and Ibrance and new RSV vaccine, Abrysvo declined in the quarter. Pfizer's COVID revenues include direct sales and alliance revenues from its ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now ... trials prior to the approval of Abrysvo (manufactured by Pfizer) and Arexvy (manufactured by ...

The Respiratory Syncytial Virus Vaccine helps against the condition known as RSV and ... information for Abrysvo (Respiratory Syncytial Virus Vaccine) manufactured by Pfizer Inc. and Arexvy ...

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized ... In a earnings report Tuesday, Pfizer said sales of its vaccine Abrysvo fell 62% year over year ...